Basic Stats
| CIK | 1584371 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to IceCure Medical Ltd
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| September 4, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES F-3 IceCure Medical Ltd. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Ordinary Shares, |
|
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 (Report No. 2) Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Addres |
|
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: September 2025 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal |
|
| September 4, 2025 |
Exhibit 99.1 IceCure’s ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy Independent study reports pain scores declined from a median of 8 on a scale of 0-10 to a median of 0 for patients who had ProSense® cryoablation procedures ProSense® is FDA cleared and approved in the European Union for gynecological indications CAESAREA, Israel, September 4, 202 |
|
| September 4, 2025 |
As filed with the Securities and Exchange Commission on September 4, 2025 As filed with the Securities and Exchange Commission on September 4, 2025 Registration No. |
|
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 (Report No. 3) Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address o |
|
| August 13, 2025 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Cautionary Statement Regarding Forward-Looking Statements Certain information included herein may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Forward-looking statements are often characterized by th |
|
| August 13, 2025 |
Exhibit 99.3 IceCure Reports Financial & Operational Results for the First Half of 2025 $10 million two-times over-subscribed rights offering creates cash runway to anticipated FDA marketing authorization decision for ProSense® in women aged 70+ with early-stage low risk breast cancer Conference call to be held today at 11:00 am Eastern Time CAESAREA, Israel, August 13, 2025 – IceCure Medical Ltd. |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 (Report No. 2) Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address o |
|
| August 13, 2025 |
Exhibit 99.1 ICECURE MEDICAL LTD. UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEET (U.S. dollars in thousands, except share data and per share data) As of June 30, As of December 31, 2025 2024 ASSETS CURRENT ASSETS Cash and cash equivalents 5,383 7,564 Trade receivables 122 221 Inventory 2,329 1,988 Prepaid expenses and other receivables 1,186 981 Total current assets 9,020 10,754 NON-CURREN |
|
| August 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of August 2025 Commission File Number: 001-40753 ICECURE MEDICAL Ltd. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal e |
|
| August 1, 2025 |
As filed with the Securities and Exchange Commission on August 1, 2025 As filed with the Securities and Exchange Commission on August 1, 2025 Registration No. |
|
| August 1, 2025 |
Exhibit 99.2 ICECURE MEDICAL LTD. CEASEREA, ISRAEL PROXY STATEMENT SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON SEPTEMBER 1, 2025 This proxy statement (the “Proxy Statement”) is being solicited by the board of directors (the “Board of Directors”) of IceCure Medical Ltd. (the “Company”) for use at the Company’s special general meeting of shareholders (the “Meeting”) to be held at on Monday |
|
| August 1, 2025 |
ICECURE MEDICAL Ltd. Notice of SPECIAL General Meeting of shareholders Exhibit 99.1 Dear IceCure Medical Ltd. Shareholder: We cordially invite you to attend the Special General Meeting of Shareholders (the “Meeting”) of IceCure Medical Ltd. (the “Company”), to be held on at, or at any adjournment or postponement thereof, by means of remote communication at the following link: https://teams.microsoft.com/dl/launcher/launcher.html?url=%2F%23%2Fl%2Fmeetup-join%2F19% 3Am |
|
| August 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: August 2025 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal ex |
|
| August 1, 2025 |
Exhibit 99.1 IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million CAESAREA, Israel, July 29, 2025 /PRNewswire/ - IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to |
|
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of July 2025 (Report No. 5) Commission File Number: 001-40753 ICECURE MEDICAL Ltd. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| July 28, 2025 |
ICECURE MEDICAL Ltd. Notice of SPECIAL General Meeting of shareholders Exhibit 99.1 Dear IceCure Medical Ltd. Shareholder: We cordially invite you to attend the Special General Meeting of Shareholders (the “Meeting”) of IceCure Medical Ltd. (the “Company”), to be held on at, or at any adjournment or postponement thereof, by means of remote communication at the following link: Join the meeting now At the Meeting, shareholders will be asked to consider and vote on the |
|
| July 28, 2025 |
Prospectus Supplement No. 2 (To Prospectus dated July 9, 2025, as supplemented by Prospectus Supplement No. 1, dated July 16, 2025) Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-288062 ICECURE MEDICAL LTD. An Aggregate of $10,000,000 in Non-Transferable Subscription Rights to purchase up to 10,000,000 Units, at a Subscription Price of $1.00 per Unit, consisting of an aggregate of |
|
| July 28, 2025 |
ICECURE MEDICAL LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS Exhibit 99.3 ICECURE MEDICAL LTD. PROXY THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoints, Mr. Eyal Shamir, Chief Executive Officer and Director, Mr. Ronen Tsimerman, Chief Financial Officer, as agents and proxies of the undersigned, with full power of substitution to each of them, to represent and to vote on behalf of the undersigned all the ordinary shar |
|
| July 28, 2025 |
Exhibit 99.2 ICECURE MEDICAL LTD. CEASEREA, ISRAEL PROXY STATEMENT SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON SEPTEMBER 1, 2025 This proxy statement (the “Proxy Statement”) is being solicited by the board of directors (the “Board of Directors”) of IceCure Medical Ltd. (the “Company”) for use at the Company’s special general meeting of shareholders (the “Meeting”) to be held at on Monday |
|
| July 25, 2025 |
Exhibit 99.1 IceCure’s ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation Breast surgeon, Professor Eisuke Fukuma, a highly regarded cryoablation expert & ProSense® user at Kameda Medical Center, presented updated breast cancer cryoablation data from an independent study of over 600 women from 2006 to 202 |
|
| July 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: July 2025 (Report No. 4) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| July 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of July 2025 (Report No. 3) Commission File Number: 001-40753 ICECURE MEDICAL Ltd. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| July 16, 2025 |
Exhibit 99.2 ICECURE MEDICAL LTD. CEASEREA, ISRAEL PROXY STATEMENT ANNUAL AND SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 20, 2025 This proxy statement (the “Proxy Statement”) is being solicited by the board of directors (the “Board of Directors”) of IceCure Medical Ltd. (the “Company”) for use at the Company’s annual and special general meeting of shareholders (the “Meeting”) to |
|
| July 16, 2025 |
ICECURE MEDICAL LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS Exhibit 99.3 ICECURE MEDICAL LTD. PROXY THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoints, Mr. Eyal Shamir, Chief Executive Officer and Director, Mr. Ronen Tsimerman, Chief Financial Officer, and each of them, agents and proxies of the undersigned, with full power of substitution to each of them, to represent and to vote on behalf of the undersigned all th |
|
| July 16, 2025 |
ICECURE MEDICAL Ltd. Notice of Annual and SPECIAL General Meeting of shareholders Exhibit 99.1 Dear IceCure Medical Ltd. Shareholder: We cordially invite you to attend the Annual and Special General Meeting of Shareholders (the “Meeting”) of IceCure Medical Ltd. (the “Company”), to be held on Wednesday, August 20, 2025 at 18:30 Israel time, or at any adjournment or postponement thereof, by means of remote communication at the following link: Join the meeting now https://eu-cent |
|
| July 16, 2025 |
Prospectus Supplement (To Prospectus dated July 9, 2025) Filed Pursuant to Rule 424(b)(3) Registration Statement No. |
|
| July 10, 2025 |
IceCure Announces Commencement of Rights Offering Exhibit 99.1 IceCure Announces Commencement of Rights Offering CAESAREA, Israel, July 10, 2025 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it has commenced its previously disclosed rights offering (the |
|
| July 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: July 2025 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| July 9, 2025 |
Prospectus Filed Pursuant to Rule 424(b)(3) Registration No. 333-288062 IceCure Medical Ltd. An Aggregate of $10,000,000 in Non-Transferable Subscription Rights to purchase up to 10,000,000 Units, at a Subscription Price of $1.00 per Unit, consisting of an aggregate of up to 10,000,000 Ordinary Shares and Warrants to purchase up to 10,000,000 Ordinary Shares 10,000,000 Units, at a Subscription Pri |
|
| July 7, 2025 |
As filed with the Securities and Exchange Commission on July 7, 2025 As filed with the Securities and Exchange Commission on July 7, 2025 Registration No. |
|
| July 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: July 2025 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal exec |
|
| July 3, 2025 |
IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025 Exhibit 99.1 IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025 CAESAREA, Israel, July 3, 2025 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced preliminary financial re |
|
| July 3, 2025 |
As filed with the Securities and Exchange Commission on July 3, 2025 As filed with the Securities and Exchange Commission on July 3, 2025 Registration No. |
|
| July 3, 2025 |
IceCure Medical Ltd. 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel IceCure Medical Ltd. 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel July 3, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: IceCure Medical Ltd. (CIK 0001584371) Registration Statement No. 333-288062 on Form F-1 (the “Registration Statement”) Ladies and Gentlemen: IceCure Medical Ltd. (the “Registrant”) hereby requ |
|
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: June 2025 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| June 25, 2025 |
Exhibit 99.3 FORM OF LETTER TO BROKERS AND OTHER NOMINEES ICECURE MEDICAL LTD. NON-TRANSFERABLE RIGHTS TO PURCHASE UP TO 10,000,000 UNITS, REPRESENTING UP TO 10,000,000 ORDINARY SHARES AND WARRANTS TO PURCHASE UP TO 10,000,000 ORDINARY SHARES or PRE-FUNDED WARRANTS TO PURCHASE UP TO 10,000,000 ORDINARY SHARES AND WARRANTS TO PURCHASE UP TO 10,000,000 ORDINARY SHARES THE RIGHTS ARE EXERCISABLE UNTI |
|
| June 25, 2025 |
Exhibit 99.2 ICECURE MEDICAL LTD. NON-TRANSFERABLE RIGHTS TO PURCHASE UP TO 10,000,000 UNITS, REPRESENTING UP TO 10,000,000 ORDINARY SHARES AND WARRANTS TO PURCHASE UP TO 10,000,000 ORDINARY SHARES or PRE-FUNDED WARRANTS TO PURCHASE UP TO 10,000,000 ORDINARY SHARES AND WARRANTS TO PURCHASE UP TO 10,000,000 ORDINARY SHARES THE RIGHTS ARE EXERCISABLE UNTIL 5:00 P.M., NEW YORK CITY TIME, ON JULY 28, |
|
| June 25, 2025 |
BENEFICIAL OWNER ELECTION FORM Exhibit 99.5 BENEFICIAL OWNER ELECTION FORM The undersigned acknowledge(s) receipt of your letter and the enclosed materials referred to therein relating to the distribution in a rights offering (the “Rights Offering”) by IceCure Medical Ltd. (the “Company”), to the holders of record (the “Record Holders”) of its ordinary shares, no par value per share (the “Ordinary Shares”), as of 5:00 p.m., New |
|
| June 25, 2025 |
Exhibit 99.1 INSTRUCTIONS AS TO USE OF ICECURE MEDICAL LTD.’s RIGHTS CERTIFICATE CONSULT THE INFORMATION AGENT, YOUR BANK OR BROKER AS TO ANY QUESTIONS The following instructions relate to the distribution of rights (the “Rights Offering”) by IceCure Medical Ltd., a company incorporated under the laws of the State of Israel (“Company”), to all holders of record (the “Record Holders”) of its ordina |
|
| June 25, 2025 |
Exhibit 99.4 FORM OF LETTER TO CLIENTS OF BROKERS AND OTHER NOMINEES ICECURE MEDICAL LTD. NON-TRANSFERABLE RIGHTS TO PURCHASE UP TO 10,000,000 UNITS, REPRESENTING UP TO 10,000,000 ORDINARY SHARES AND WARRANTS TO PURCHASE UP TO 10,000,000 ORDINARY SHARES OR PRE-FUNDED WARRANTS TO PURCHASE UP TO 10,000,000 ORDINARY SHARES AND WARRANTS TO PURCHASE UP TO 10,000,000 ORDINARY SHARES THE RIGHTS ARE EXERC |
|
| June 25, 2025 |
ICECURE MEDICAL LTD. FORM OF DEALER-MANAGER AGREEMENT Exhibit 1.1 ICECURE MEDICAL LTD. FORM OF DEALER-MANAGER AGREEMENT [●], 2025 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 As Dealer-Manager Ladies and Gentlemen: The following will confirm our agreement relating to the proposed rights offering (the “Rights Offering”) to be undertaken by IceCure Medical Ltd., a company organized under the laws of the State of Israel (the “Company”) |
|
| June 25, 2025 |
As filed with the Securities and Exchange Commission on June 25, 2025 As filed with the Securities and Exchange Commission on June 25, 2025 Registration No. |
|
| June 25, 2025 |
Filed Pursuant to Rule 433 Issuer Free Writing Prospectus Dated June 25, 2025 Relating to Preliminary Prospectus, dated June 25, 2025 Registration No. |
|
| June 25, 2025 |
PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT ICECURE MEDICAL LTD. Exhibit 4.3 PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT ICECURE MEDICAL LTD. Warrant Shares: Date of Issuance: , 2025 THIS PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof |
|
| June 25, 2025 |
Exhibit 10.12 ICECURE MEDICAL LTD. and Vstock Transfer, LLC, as Warrant Agent Form of Warrant Agency Agreement Dated as of , 2025 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2025 (“Agreement”), by and between IceCure Medical Ltd., a company organized under the laws of the State of Israel (the “Company”), and VStock Transfer, LLC (“VStock” or the “Warrant Agent”). W I T N E S S |
|
| June 25, 2025 |
Exhibit 99.6 NOMINEE HOLDER CERTIFICATION The undersigned, a broker, dealer, custodian bank, trustee, depositary or other nominee holder of subscription rights (the “Rights”) to purchase Units (each, a “Unit”) consisting of one ordinary share, no par value per share (“Ordinary Share”) and one warrant to purchase one Ordinary Share (the “Warrant”) of IceCure Medical Ltd. (the “Company”), pursuant t |
|
| June 25, 2025 |
IceCure Announces Record Date for Rights Offering for Up to $10 Million Exhibit 99.1 IceCure Announces Record Date for Rights Offering for Up to $10 Million CAESAREA, Israel, June 25, 2025 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that its board of directors approved a rights |
|
| June 25, 2025 |
Exhibit 4.1 THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN ICECURE MEDICAL, LTD.’S PROSPECTUS DATED [●], 2025 (THE “PROSPECTUS”) AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS ARE AVAILABLE UPON REQUEST FROM BROADRIDGE CORPORATE ISSUER SOLUTIONS, LLC, THE INFORMATION AGENT, BY TELEPHONE ((888) 789-8409) OR EMAIL ([email protected]). IceCure Medical Lt |
|
| June 25, 2025 |
FORM OF ORDINARY SHARE PURCHASE WARRANT ICECURE MEDICAL LTD. Exhibit 4.2 FORM OF ORDINARY SHARE PURCHASE WARRANT ICECURE MEDICAL LTD. Warrant Shares: Date of Issuance: , 2025 THIS ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial |
|
| June 16, 2025 |
SUBSCRIPTION AND INFORMATION AGENT AGREEMENT Exhibit 10.11 SUBSCRIPTION AND INFORMATION AGENT AGREEMENT This Subscription and Information Agent Agreement (the “Agreement”) is entered into as of this 19th day of May, 2025 (the “Effective Date”) by and between, IceCure Medical Ltd., organized and existing under the laws of the State of Israel (the “Company”), and Broadridge Corporate Issuer Solutions, LLC, a Company having its principal office |
|
| June 16, 2025 |
As filed with the Securities and Exchange Commission on June 16, 2025 As filed with the Securities and Exchange Commission on June 16, 2025 Registration No. |
|
| June 16, 2025 |
IceCure Medical Ltd. 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel IceCure Medical Ltd. 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel June 16, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: IceCure Medical Ltd. (CIK 0001584371) Registration Statement No. 333-282652 on Form F-1, as amended Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities Act of 1933, as |
|
| June 16, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form F-1 (Form Type) IceCure Medical Ltd. |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: June 2025 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal exec |
|
| June 9, 2025 |
Exhibit 99.1 IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes IceCure has 20+ patents in the U.S. and the Company anticipates further market traction upon FDA’s marketing authorization decision in early-stage breast cancer CAESAREA, Israel, June 9, 2025 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Compa |
|
| May 28, 2025 |
Exhibit 99.1 IceCure Medical Reports First Quarter 2025 Financial Results Recently finalized and delivered proposed post market study plan to the FDA; Awaiting marketing authorization decision for ProSense® in women aged 70+ with early-stage low risk breast cancer Continues to see rising interest in North America for ProSense® Conference call to be held today at 10:00 am Eastern Time CAESAREA, Isr |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2025 (Report No. 4) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| May 23, 2025 |
As confidentially submitted to Securities and Exchange Commission on May 22, 2025. |
|
| May 21, 2025 |
Exhibit 10.1 UNSECURED LOAN AGREEMENT This Unsecured Loan Agreement (“Agreement”) is made and entered into as of May 17, 2025 (the “Effective Date”), by and between Icecure Medical Ltd. (the “Borrower”) and Epoch Partner Investments Limited (the “Lender”). WHEREAS, the Borrower requires funds in order to conduct its business activities, and for this purpose, it desires to borrow $2,000,000 from th |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 (Report No. 2) Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of p |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal execut |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: April 2025 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address o |
|
| April 30, 2025 |
Exhibit 99.1 IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer ● Final marketing authorization decision for early-stage breast cancer is expected upon the FDA’s approval of IceCure’s post-market study plan ● IceCure to engage with potential clinical sites, breast surgeons and r |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 Commission file number: 001-40753 ICECURE MEDICAL Ltd. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal exec |
|
| April 10, 2025 |
Exhibit 99.2 ICECURE MEDICAL LTD. CEASEREA, ISRAEL PROXY STATEMENT SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 15, 2025 The enclosed proxy statement is being solicited by the board of directors (the “Board of Directors”) of IceCure Medical Ltd. (the “Company”) for use at the Company’s special general meeting of shareholders (the “Meeting”) to be held at on Thursday, May 15, 2025 at 1 |
|
| April 10, 2025 |
ICECURE MEDICAL LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS Exhibit 99.3 ICECURE MEDICAL LTD. PROXY THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoints, Mr. Eyal Shamir, Chief Executive Officer and Mr. Ronen Tsimerman, Chief Financial Officer, as agents and proxies of the undersigned, with full power of substitution to each of them, to represent and to vote on behalf of the undersigned all the Ordinary Shares of IceC |
|
| April 10, 2025 |
ICECURE MEDICAL Ltd. Notice of SPECIAL General Meeting of shareholders Exhibit 99.1 Dear IceCure Medical Ltd. Shareholders: We cordially invite you to attend the Special General Meeting of Shareholders of IceCure Medical Ltd. (the “Meeting”), to be held on Thursday, May 15, 2025 at 16:00 Israel time, or at any adjournment or postponement thereof, at the Company’s offices at 7 Ha’Eshel St., Caesarea, 3079504, Israel. At the Meeting, shareholders will be asked to consi |
|
| March 27, 2025 |
IceCure Medical Ltd. Insider Trading Policy Effective January 12 , 2022 Amended March 26, 2025 Exhibit 11.1 IceCure Medical Ltd. Insider Trading Policy Effective January 12 , 2022 Amended March 26, 2025 I. Introduction This policy determines acceptable transactions in the securities of IceCure Medical Ltd. (the “Company”) by our employees, directors, consultants and other related persons. This policy arises from the Company’s status as a public company whose shares are traded on the Nasdaq |
|
| March 27, 2025 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Ronen Tsimerman, certify that: 1. I have reviewed this annual report on Form 20–F of IceCure Medical Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstanc |
|
| March 27, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2024 (the “Report”) by IceCure Medical Ltd. (the “Company”), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with the |
|
| March 27, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in Registration Statements Nos. 333-258660 and 333-267272 on Form F-3 and Nos. 333-262620, 333-264578, 333-270982, and 333-281587 on Form S-8 of our report dated March 27, 2025, relating to the consolidated financial statements of IceCure Medical Ltd. appearing in this Annual Report o |
|
| March 27, 2025 |
Exhibit 2.1 Description of Share Capital The following description of IceCure Medical Ltd. (the “Company”) share capital, provisions of articles of association (“Articles”) as may be amended and restated from time to time, and Israeli law are summaries and do not purport to be complete, and is qualified in its entirety by reference to, the provisions of our Articles as well as the Israeli law and |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2025 (Report No.5) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| March 27, 2025 |
IceCure Medical Ltd. Insider Trading Policy Effective January 12 , 2022 Amended March 26, 2025 Exhibit 11.1 IceCure Medical Ltd. Insider Trading Policy Effective January 12 , 2022 Amended March 26, 2025 I. Introduction This policy determines acceptable transactions in the securities of IceCure Medical Ltd. (the “Company”) by our employees, directors, consultants and other related persons. This policy arises from the Company’s status as a public company whose shares are traded on the Nasdaq |
|
| March 27, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2024 (the “Report”) by IceCure Medical Ltd. (the “Company”), the undersigned, as the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with the |
|
| March 27, 2025 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Eyal Shamir, certify that: 1. I have reviewed this annual report on Form 20–F of IceCure Medical Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances u |
|
| March 27, 2025 |
Exhibit 2.1 Description of Share Capital The following description of IceCure Medical Ltd. (the “Company”) share capital, provisions of articles of association (“Articles”) as may be amended and restated from time to time, and Israeli law are summaries and do not purport to be complete, and is qualified in its entirety by reference to, the provisions of our Articles as well as the Israeli law and |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANTTO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. |
|
| March 27, 2025 |
Exhibit 99.1 IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America Expecting FDA decision on marketing authorization for early-stage low risk breast cancer with endocrine therapy Positive ProSense® results were reported through 33 peer-reviewed journals and medical conferences during 2024 Conference call to be held today at 10:00 am Eastern Tim |
|
| March 27, 2025 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Eyal Shamir, certify that: 1. I have reviewed this annual report on Form 20–F of IceCure Medical Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances u |
|
| March 27, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2024 (the “Report”) by IceCure Medical Ltd. (the “Company”), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with the |
|
| March 27, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2024 (the “Report”) by IceCure Medical Ltd. (the “Company”), the undersigned, as the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with the |
|
| March 27, 2025 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Ronen Tsimerman, certify that: 1. I have reviewed this annual report on Form 20–F of IceCure Medical Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstanc |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANTTO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. |
|
| March 27, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in Registration Statements Nos. 333-258660 and 333-267272 on Form F-3 and Nos. 333-262620, 333-264578, 333-270982, and 333-281587 on Form S-8 of our report dated March 27, 2025, relating to the consolidated financial statements of IceCure Medical Ltd. appearing in this Annual Report o |
|
| March 20, 2025 |
Exhibit 99.1 IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer IceCure working in close collaboration with FDA towards De Novo decision CAESAREA, Israel, March 20, 2025 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation tech |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2025 (Report No. 4) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address o |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2025 (Report No. 3) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address o |
|
| March 18, 2025 |
Exhibit 99.1 IceCure’s ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference ● IceCure exhibited at the prestigious event in Vienna, Austria attended by oncologists, breast surgeons ● An abstract on ICE3 study results by Dr. Richard Fine was accepted and included in the poster presentation gallery ● An independent study by Dr. Ava Kwong evalu |
|
| March 17, 2025 |
Exhibit 99.1 IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology This latest IP win rounds out protection for the cryogenic pump in major global market following grants for the same patent in the U.S., Europe and Japan CAESAREA, Israel, March 17, 2025 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”) |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2025 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address o |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2025 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal exe |
|
| March 10, 2025 |
Exhibit 99.1 Breast Cancer Patients who Underwent IceCure’s ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery ● Independent study published in Gland Surgery and conducted at Kameda Medical Center in Japan by ProSense® users including Dr. Kizuki Matsumoto and Dr. Eisuke Fukuma ● Patients who underwent cryoablation compare |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: February 2025 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Addres |
|
| February 24, 2025 |
Exhibit 99.1 IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel Application covering a wide range of indications is in line with trends in de-escalation of surgery and growth in minimally invasive cryoablation procedures, pointing to strong potential for increasing demand CAESAREA, Israel, February 24, 2025 – IceCure Medical Ltd. (Nasdaq: IC |
|
| February 4, 2025 |
Exhibit 99.1 IceCure’s ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA’s Market Authorization Decision ● Two independent studies of ProSense® cryoablation in breast cancer were presented, one of which won the Highest Scoring Abstract Award in its category |
|
| February 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: February 2025 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: January 2025 (Report No. 5) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address |
|
| January 27, 2025 |
Exhibit 99.1 IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China Seeks to expand regulatory approval in China where IceSense3 has already been approved CAESAREA, Israel, January 27, 2025 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alt |
|
| January 13, 2025 |
EX-99.1 2 ea022734603ex99-1icecure.htm PRESS RELEASE DATED JANUARY 13, 2025 TITLED "ICECURE MEDICAL CEO ISSUES LETTER TO SHAREHOLDERS & REPORTS INCREASE OF 42% IN PROSENSE SALES FOR 2024 IN NORTH AMERICA." Exhibit 99.1 IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America ● Increase in sales of ProSense®, based on preliminary unaud |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: January 2025 (Report No. 4) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address |
|
| January 13, 2025 |
Up to $13,960,500 Ordinary Shares IceCure Medical Ltd. PROSPECTUS SUPPLEMENT (To Prospectus dated September 14, 2022) Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| January 13, 2025 |
ICECURE MEDICAL LTD. Up to US$13,960,500 of Ordinary Shares EQUITY DISTRIBUTION AGREEMENT Exhibit 10.1 ICECURE MEDICAL LTD. Up to US$13,960,500 of Ordinary Shares EQUITY DISTRIBUTION AGREEMENT January 13, 2025 Maxim Group LLC 300 Park Avenue New York, New York 10022 Ladies and Gentlemen: This Equity Distribution Agreement (this “Agreement”) is entered into between IceCure Medical Ltd., a company formed under the laws of the State of Israel (the “Company”) and Maxim Group LLC (the “Agen |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: January 2025 (Report No. 3) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: January 2025 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address |
|
| January 6, 2025 |
IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule Exhibit 99.1 IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule CAESAREA, Israel, January 6, 2025 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has received a notifica |
|
| January 3, 2025 |
Exhibit 99.1 European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology XSense™ system’s innovative cryogenic connector technology designed to improve safety and maintain the integrity of cryogen used in the cryoablation procedure CAESAREA, Israel, January 3, 2025 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Com |
|
| January 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: January 2025 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal e |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: December 2024 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Addres |
|
| December 5, 2024 |
Exhibit 99.1 IceCure’s ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results ● Data confirm previous results showing that ProSense® cryoablation is highly effective for kidney tumors < 3 cm and a safe procedure for kidney tumors < 5 cm in people ineligible for surgery ● Interim results presented at the Isr |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: December 2024 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal |
|
| November 26, 2024 |
EX-99.1 2 ea022263501ex99-1icecure.htm PRESS RELEASE DATED NOVEMBER 26, 2024 TITLED "ICECURE MEDICAL REPORTS 36% SALES GROWTH IN THE FIRST NINE MONTHS OF 2024 DRIVEN BY GLOBAL ADOPTION OF PROSENSE CRYOABLATION" Exhibit 99.1 IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation FDA Marketing Authorization Decision on Early Stag |
|
| November 26, 2024 |
6-K 1 ea0222635-6kicecure.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: November 2024 (Report No. 3) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into Englis |
|
| November 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: November 2024 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Addres |
|
| November 25, 2024 |
Exhibit 99.1 IceCure’s Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan’s Patent Office Invention facilitates treatment of larger tumors and is a significant leap forward in the field of cryoablation CAESAREA, Israel, November 25, 2024 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoa |
|
| November 14, 2024 |
ICCM / IceCure Medical Ltd / Epoch Partner Investments Ltd - AMENDMENT NO. 3 Passive Investment SC 13G/A 1 y1113240sc13ga3.htm AMENDMENT NO. 3 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 3)* IceCure Medical Ltd. (Name of Issuer) Ordinary Shares, no par value (Title of C |
|
| November 8, 2024 |
ORDINARY SHARE PURCHASE WARRANT ICECURE MEDICAL LTD. Exhibit 4.1 ORDINARY SHARE PURCHASE WARRANT ICECURE MEDICAL LTD. Warrant Shares: Date of Issuance: , 2024 THIS ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise |
|
| November 8, 2024 |
Exhibit 99.1 FDA Advisory Panel Votes in Favor of IceCure’s ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer FDA decision on marketing authorization expected in the first quarter of 2025 CAESAREA, Israel, November 8, 2024 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology th |
|
| November 8, 2024 |
As filed with the Securities and Exchange Commission on November 8, 2024 As filed with the Securities and Exchange Commission on November 8, 2024 Registration No. |
|
| November 8, 2024 |
Exhibit 10.10 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of [●], 2024, between IceCure Medical Ltd, a company formed under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchase |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: November 2024 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal |
|
| November 5, 2024 |
Exhibit 1.1 PLACEMENT AGENCY AGREEMENT , 2024 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Roth Capital Partners, LLC 57 W. 57th St., 18th Fl. New York, NY 10019 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), IceCure Medical Ltd., a company organized under the laws of the State of Israel (the “Company”), hereby agrees to sell up |
|
| November 5, 2024 |
PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT ICECURE MEDICAL LTD. Exhibit 4.2 PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT ICECURE MEDICAL LTD. Warrant Shares: Date of Issuance: , 2024 THIS PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof |
|
| November 5, 2024 |
Exhibit 10.10 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of [●], 2024, between IceCure Medical Ltd, a company formed under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchase |
|
| November 5, 2024 |
As filed with the Securities and Exchange Commission on November 5, 2024 As filed with the Securities and Exchange Commission on November 5, 2024 Registration No. |
|
| November 5, 2024 |
Exhibit 10.11 ICECURE MEDICAL LTD. and Vstock Transfer, LLC, as Warrant Agent Warrant Agency Agreement Dated as of , 2024 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2024 (“Agreement”), by and between IceCure Medical Ltd., a company organized under the laws of the State of Israel (the “Company”), and VStock Transfer, LLC (“VStock” or the “Warrant Agent”). W I T N E S S E T H W |
|
| November 5, 2024 |
ORDINARY SHARE PURCHASE WARRANT ICECURE MEDICAL LTD. Exhibit 4.1 ORDINARY SHARE PURCHASE WARRANT ICECURE MEDICAL LTD. Warrant Shares: Date of Issuance: , 2024 THIS ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise |
|
| November 5, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form F-1 (Form Type) IceCure Medical Ltd. |
|
| October 21, 2024 |
Exhibit 99.1 IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System Innovative cryogenic system connector technology designed to improve usability and maintain the integrity of cryogen used in the cryoablation procedure CAESAREA, Israel, October 21, 2024 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Compa |
|
| October 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: October 2024 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address |
|
| October 15, 2024 |
As filed with the Securities and Exchange Commission on October 15, 2024 As filed with the Securities and Exchange Commission on October 15, 2024 Registration No. |
|
| October 15, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form F-1 (Form Type) IceCure Medical Ltd. |
|
| October 7, 2024 |
Exhibit 99.1 IceCure’s ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference ● ICE3 trial results presentation by Co-Principal Investigator Dr. Kenneth Tomkovich wins EUSOBI 2024 Abstract Award ● THERMAC Trial on Treatment of Breast Cancer with Percutaneous Thermal Ablation (cryoablation, radiofrequency, and microwave) win |
|
| October 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: October 2024 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal e |
|
| September 24, 2024 |
Exhibit 99.1 IceCure’s ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate ● Publication comes ahead of the FDA Advisory Panel Meeting for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer scheduled for November 7 |
|
| September 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: September 2024 (Report No. 3) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Addre |
|
| September 16, 2024 |
Exhibit 99.1 Study Published in the British Journal of Radiology Demonstrates IceCure’s ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues ● Liquid nitrogen- (LN2) based ProSense® found to have favorable safety compared to argon-based cryoablation systems, as well as being more cost effective and easier to manage ● Independent stu |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: September 2024 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Addre |
|
| September 12, 2024 |
Exhibit 99.1 IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024 ● Public forum to evaluate ProSense® cryoablation as a minimally invasive alternative to lumpectomy for an estimated 70,000 women diagnosed in U.S. annually with early-stage low risk breast cancer ● FDA decision regarding marke |
|
| September 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: September 2024 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal |
|
| August 28, 2024 |
Exhibit 99.1 USPTO Grants Notice of Allowance for Additional Patent on IceCure’s Novel Cryogenic Pump Technology: Reinforces IceCure’s Global IP Leadership in Cryoablation Technologies ● Further broadens the uses and applications of IceCure’s cryoablation platform into a wide range of technology fields ● Over 50 patents issued and allowed worldwide for IceCure’s platform cryoablation technology CA |
|
| August 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: August 2024 (Report No. 5) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address |
|
| August 20, 2024 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Cautionary Statement Regarding Forward-Looking Statements Certain information included herein may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Forward-looking statements are often characterized by th |
|
| August 20, 2024 |
Exhibit 99.1 ICECURE MEDICAL LTD. UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEET (U.S. dollars in thousands, except share data and per share data) As of June 30, As of December 31, 2024 2023 ASSETS CURRENT ASSETS Cash and cash equivalents 9,652 10,533 Short-term deposits 807 529 Trade receivables 325 103 Inventory 1,969 2,275 Prepaid expenses and other receivables 574 744 Total current ass |
|
| August 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 (Report No. 4) Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address o |
|
| August 20, 2024 |
Exhibit 99.3 IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets Near-term regulatory and operating catalysts have potential to accelerate adoption of ProSense® for treatment of early-stage, low risk breast cancer Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel |
|
| August 16, 2024 |
As filed with the Securities and Exchange Commission on August 16, 2024 As filed with the Securities and Exchange Commission on August 16, 2024 Registration No. |
|
| August 16, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) IceCure Medical Ltd. |
|
| August 14, 2024 |
Exhibit 99.1 IceCure’s ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery ● After a median follow-up of 16 months, the complete ablation rate in Luminal A and B breast cancer tumors ≤ 25mm was 100% ● Study concluded that most non-surgical patients with early-stage breast cancer accepted cryoablation when the treatment was off |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: August 2024 (Report No. 3) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: August 2024 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address |
|
| August 7, 2024 |
Exhibit 99.1 IceCure Announces Positive Data from the Largest Multi- Institutional Study of its Kind: “Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials” ● Investigator initiated independent study included higher risk patients such as those with metastatic disease, large tumors, and comorbidities, as compared to IceCure’s ICE3 study which treated early-stage breast c |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: August 2024 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal ex |
|
| July 22, 2024 |
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification Exhibit 99.1 IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification CAESAREA, ISRAEL, July 19, 2024 (GLOBE NEWSWIRE) - IceCure Medical Ltd. (Nasdaq: ICCM) (the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it has received a written notice (the “Notice”) from |
|
| July 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: July 2024 (Report No. 5) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| July 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: July 2024 (Report No. 4) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| July 22, 2024 |
Exhibit 99.1 99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure’s ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society ● Demand for minimally invasive breast cancer treatment was overarching theme of the conference ● In one independent study led by Professor Fukuma, 389 patients treated for up to 10 years had |
|
| July 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2024 (Report No. 3) Commission file number: 001-40753 ICECURE MEDICAL Ltd. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| July 16, 2024 |
Exhibit 99.2 ICECURE MEDICAL LTD. CEASEREA, ISRAEL PROXY STATEMENT SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 21, 2024 The enclosed proxy statement is being solicited by the board of directors (the “Board of Directors”) of IceCure Medical Ltd. (the “Company”) for use at the Company’s special general meeting of shareholders (the “Meeting”) to be held at on Wednesday, August 21, 20 |
|
| July 16, 2024 |
ICECURE MEDICAL LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS Exhibit 99.3 ICECURE MEDICAL LTD. PROXY THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoints, Mr. Eyal Shamir, Chief Executive Officer and Mr. Ronen Tsimerman, Chief Financial Officer, as agents and proxies of the undersigned, with full power of substitution to each of them, to represent and to vote on behalf of the undersigned all the Ordinary Shares of IceC |
|
| July 16, 2024 |
ICECURE MEDICAL Ltd. Notice of SPECIAL General Meeting of shareholders Exhibit 99.1 Dear IceCure Medical Ltd. Shareholders: We cordially invite you to attend the Special General Meeting of Shareholders of IceCure Medical Ltd. (the “Meeting”), to be held on Wednesday, August 21, 2024 at 16:00 Israel time, or at any adjournment or postponement thereof, at the Company’s offices at 7 Ha’Eshel St., Caesarea, 3079504, Israel, and by means of remote communication at the fol |
|
| July 9, 2024 |
Exhibit 99.1 European Study Provides More Evidence Supporting IceCure’s ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer ● Independent, third-party data published in highly influential peer-reviewed journal, Cancers, concluded cryoablation with ProSense® is a safe, local treatment for breast cancer with low complication rate, high complete ablation ra |
|
| July 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: July 2024 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| July 1, 2024 |
Exhibit 99.1 U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes CAESAREA, Israel, July 1, 2024 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: July 2024 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal exec |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: June 2024 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal exec |
|
| June 4, 2024 |
Exhibit 99.1 FDA to Convene Advisory Panel for Review of IceCure’s De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness Plan ● Demonstrates public health importance of assessing ProSense®’s potential to offer optimal treatment that benefits women with early-stage breast cancer ● Patients, patient advocacy groups, doctors, and the general |
|
| May 28, 2024 |
Exhibit 99.1 IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024 ● 30% sales growth reflects continued adoption of ProSense® in the U.S. and other global markets ● Major milestones achieved: O Completion of landmark ICE3 trial for breast cancer O Positive final ICE3 trial data ● Awaiting FDA Decision ● Independent studies performed |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2024 (Report No. 3) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 (Report No. 2) Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of p |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2024 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal execu |
|
| May 7, 2024 |
Exhibit 99.1 Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure’s ProSense®, Adding to Continued Positive Data Published Globally ● Study published in the peer reviewed journal Breast Cancer ● Excellent cosmetic outcomes, high degree of patient satisfaction, and improved quality of life post-cryoablation ● Strategic dist |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2024 (Report No. 4) Commission file number: 001-40753 ICECURE MEDICAL Ltd. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| April 15, 2024 |
Exhibit 99.2 ICECURE MEDICAL LTD. CEASEREA, ISRAEL PROXY STATEMENT ANNUAL AND SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 20, 2024 The enclosed proxy statement is being solicited by the board of directors (the “Board of Directors”) of IceCure Medical Ltd. (the “Company”) for use at the Company’s annual and special general meeting of shareholders (the “Meeting”) to be held at on Monda |
|
| April 15, 2024 |
ICECURE MEDICAL LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS Exhibit 99.3 ICECURE MEDICAL LTD. PROXY THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoints, Mr. Eyal Shamir, Chief Executive Officer and Director, Mr. Ronen Tsimerman, Chief Financial Officer, and each of them, agents and proxies of the undersigned, with full power of substitution to each of them, to represent and to vote on behalf of the undersigned all th |
|
| April 15, 2024 |
ICECURE MEDICAL Ltd. Notice of Annual and SPECIAL General Meeting of shareholders Exhibit 99.1 Dear IceCure Medical Ltd. Shareholders: We cordially invite you to attend the Annual and Special General Meeting of Shareholders of IceCure Medical Ltd. (the “Meeting”), to be held on Monday, May 20, 2024 at 16:00 Israel time, or at any adjournment or postponement thereof, at the Company’s offices at 7 Ha’Eshel St., Caesarea, 3079504, Israel, and by means of remote communication at th |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: April 2024 (Report No. 3) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address o |
|
| April 15, 2024 |
Exhibit 99.1 IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer ● Data presentation at highly influential American Society of Breast Surgeons (“ASBrS”) Annual Meeting by Dr. Richard Fine wins Scientific Impac |
|
| April 3, 2024 |
ICECURE MEDICAL LTD. 2024 EMPLOYEE EQUITY INCENTIVE PLAN Exhibit 4.9 ICECURE MEDICAL LTD. 2024 EMPLOYEE EQUITY INCENTIVE PLAN CONTENTS Contents CONTENTS i 1. PURPOSE OF THE ESOP 1 2. DEFINITIONS 1 3. ADMINISTRATION OF THE ESOP 4 4. DESIGNATION OF PARTICIPANTS 6 5. DESIGNATION OF AWARDS PURSUANT TO SECTION 102 7 6. TRUSTEE 8 7. SHARES RESERVED FOR THE ESOP; RESTRICTION THEREON 8 8. EXERCISE PRICE 9 9. TERM AND EXERCISE AND SETTLEMENT OF AWARDS 10 10. VES |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANTTO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. |
|
| April 3, 2024 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Ronen Tsimerman, certify that: 1. I have reviewed this annual report on Form 20–F of IceCure Medical Ltd. (the “company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstanc |
|
| April 3, 2024 |
ICECURE MEDICAL LTD. (the “Company”) CLAWBACK POLICY Effective as of November 15, 2023 Exhibit 97.1 ICECURE MEDICAL LTD. (the “Company”) CLAWBACK POLICY Effective as of November 15, 2023 Background The Board of Directors of the Company (the “Board”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. Th |
|
| April 3, 2024 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2023 (the “Report”) by IceCure Medical Ltd. (the “company”), the undersigned, as the Chief Executive Officer of the company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with the |
|
| April 3, 2024 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2023 (the “Report”) by IceCure Medical Ltd. (the “company”), the undersigned, as the Chief Financial Officer of the company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with the |
|
| April 3, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statements on Form F-3 (Registration Nos. 333-258660 and 333-267272) and on Form S-8 (Registration Nos. 333-270982, 333-264578, and 333-262620) of our report dated April 3, 2024, relating to the consolidated financial statements of IceCure Medical Ltd. appearing in |
|
| April 3, 2024 |
Exhibit 2.1 Description of Share Capital The following description of IceCure Medical Ltd. (the “Company”) share capital, provisions of articles of association (“Articles”) as may be amended and restated from time to time, and Israeli law are summaries and do not purport to be complete, and is qualified in its entirety by reference to, the provisions of our Articles as well as the Israeli law and |
|
| April 3, 2024 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Eyal Shamir, certify that: 1. I have reviewed this annual report on Form 20–F of IceCure Medical Ltd. (the “company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances u |
|
| April 3, 2024 |
Exhibit 99.1 IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance Conference call to be held today at 10:00 am Eastern Time; Focus on U.S. market for ProSense® in breast cancer indication CAESAREA, |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: April 2024 (Report No.2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| April 2, 2024 |
Exhibit 99.1 IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes Continuous innovation as a global leader in minimally invasive liquid-nitrogen based cryoablation systems CAESAREA, Israel, April 2, 2024 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or the “Company”), developer of the ProSense® System, a minimally-invasive cryoablation technology that destro |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: April 2024 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal exe |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2024 (Report No. 3) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address o |
|
| March 19, 2024 |
Exhibit 99.1 IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy ● Expects to submit full dataset to the FDA in April for marketing authorization of ProSense® for minimally invasive treatment of early-stage breast cancer ● St |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2024 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address o |
|
| March 12, 2024 |
Exhibit 99.1 IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes ● Innovating as a global leader in cryoablation technologies, with 42 patents issued and allowed ● Cryogenic flow control enhances the efficacy and precision of cryoablation procedures CAESAREA, Israel, March 12, 2024 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or th |
|
| March 4, 2024 |
Exhibit 99.1 IceCure’s ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024 ● MRI reveals disappearance of hemorrhagic signal and development of necrotic changes ● Pain reduced from a median of 7 on a scale of 0 - 10 to a median of 1, with some patients reporting 0 CAESAREA, Israel, March 4, 2024 – IceCure Medical Ltd. (Nasdaq: ICCM) ( |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2024 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal exe |
|
| February 26, 2024 |
Exhibit 99.1 Study Using IceCure’s ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer Independent study in women deemed inoperable for breast cancer reports median tumor reduction of 100% at 6 and 12 months following cryoablation CAESAREA, Israel, February 26, 2024 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or the “Company”), developer of the ProSense® System, a |
|
| February 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: February 2024 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal |
|
| January 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: January 2024 (Report No. 4) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address |
|
| January 30, 2024 |
Exhibit 99.1 U.S. FDA Grants IceCure Medical’s Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense® for Early-Stage Breast Cancer IceCure to submit full 5-year dataset from entire ICE3 study population to the FDA this spring, ahead of previous expectation CAESAREA, Israel, January 30, 2024 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or the “Company”), develo |
|
| January 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: January 2024 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address |
|
| January 12, 2024 |
ICECURE MEDICAL LTD. Up to US$9,700,000 of Ordinary Shares EQUITY DISTRIBUTION AGREEMENT Exhibit 10.1 ICECURE MEDICAL LTD. Up to US$9,700,000 of Ordinary Shares EQUITY DISTRIBUTION AGREEMENT January 12, 2024 Maxim Group LLC 300 Park Avenue New York, New York 10022 Ladies and Gentlemen: This Equity Distribution Agreement (this “Agreement”) is entered into between IceCure Medical Ltd., a company formed under the laws of the State of Israel (the “Company”) and Maxim Group LLC (the “Agent |
|
| January 12, 2024 |
IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule Exhibit 99.1 IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule CAESAREA, Israel, Jan. 12, 2024 (GLOBE NEWSWIRE) - IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or the “Company”), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it has receiv |
|
| January 12, 2024 |
Up to $9,700,000 Ordinary Shares IceCure Medical Ltd. PROSPECTUS SUPPLEMENT (To Prospectus dated September 14, 2022) Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| January 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 (Report No. 3) Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address |
|
| January 10, 2024 |
Exhibit 99.1 IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Results ● U.S. sales continue to increase with 25% jump in ProSense® system and disposable probe sales in 2023 over prior year ● ICE3 study is set for completion and final data read out CAESAREA, Israel, January 10, 2024 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or the “C |
|
| January 10, 2024 |
IceCure Medical Ltd. 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel IceCure Medical Ltd. 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel January 10, 2024 Via EDGAR Benjamin Richie Abby Adams Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, NE Washington, DC 20549 Re: IceCure Medical Ltd. Supplemental Response dated October 13, 2023 Annual Report on Form 20-F filed March 29, 2023 Fi |
|
| January 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal ex |
|
| December 13, 2023 |
Exhibit 99.1 Study Using IceCure’s ProSense® Finds: “Cryoablation Allows the Ultimate De-escalation of Surgical Therapy for Select Breast Cancer Patients” ● Independent study published in Annals of Surgical Oncology concludes cryoablation is an oncologically safe and feasible minimally invasive procedure option in lieu of surgery for patients with early-stage, low-risk breast cancer ● Study’s auth |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal e |
|
| November 29, 2023 |
IceCure’s ProSense® Deepens Regulatory Approval in India Exhibit 99.2 IceCure’s ProSense® Deepens Regulatory Approval in India ● ProSense® is already marketed and sold in India based on previous regulatory requirements and now has been re-classified due to new regulations ● Breast cancer cryoablation is already performed in India with ProSense® CAESAREA, Israel, November 29, 2023 - IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the |
|
| November 29, 2023 |
Exhibit 99.1 IceCure System Successfully Treated Kidney Cancer Tumor with 92% Disease-Free Survival Rate and 100% Secondary Local Control Rate ● Independent study concluded: o IceCure system offers significant advantage in ability to re-treat tumors that are initially resistant, achieving a subsequent local control rate of 100% o 92.4% of patients (N= 24) were discharged the day after cyroablation |
|
| November 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 (Report No.3) Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address |
|
| November 15, 2023 |
Exhibit 99.2 IceCure Medical Reports Financial Results as of and for the Nine Months Ended September 30, 2023, and Provides Update on Recent Operational Highlights ● ProSense® system and disposables sales continue upward trend compared to the equivalent prior year period ● Expanded regulatory footprint, growing body of evidenced-based data, and distribution agreements demonstrate an increasing acc |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 (Report No. 2) Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address |
|
| November 15, 2023 |
Exhibit 99.1 IceCure Medical Files Appeal with U.S. FDA Requesting a Review of its De Novo Classification for ProSense® in Early-Stage Breast Cancer ● Objective is to reopen file to address comments and find appropriate comparator group that is more representative of the patient population the Company is seeking to treat with its ProSense® system ● Company seeks to complete the review process, est |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2023 Commission file number: 001-40753 ICECURE MEDICAL Ltd. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal e |
|
| November 3, 2023 |
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification Exhibit 99.1 IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification CAESAREA, ISRAEL, November 3, 2023 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or the “Company”), a developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it has received a written no |
|
| October 13, 2023 |
ICECURE MEDICAL ltd. 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel ICECURE MEDICAL ltd. 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel October 13, 2023 Via EDGAR Jeanne Baker Terence O’Brien Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, NE Washington, DC 20549 Re: IceCure Medical Ltd. (the “Company,” “we,” “our” and similar terminology) Form 20-F filed March 29, 2023 File No. |
|
| October 5, 2023 |
Exhibit 99.1 Women Deemed Inoperable for Breast Cancer Benefitted from IceCure Medical’s ProSense as an Independent Study Performed in Italy Showed a Tumor Reduction Rate of 93.43% to 96.81% ● Disappearance of lesions and absence of residual malignant cells in Luminal-A group considered to be predictive for the complete effectiveness of the treatment ● This is the latest in a growing body of evide |
|
| October 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 (Report No.2) Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address o |
|
| October 2, 2023 |
Exhibit 99.1 Independent Study Validates IceCure’s ProSense Cryoablation is Safe & Effective Outpatient Procedure for Breast Cancer with 96.8% Success Rate ● Study was conducted in Spain with women who declined standard of care surgery ● ProSense is approved for the treatment of breast cancer throughout the European Union CAESAREA, Israel, October 2, 2023 - IceCure Medical Ltd. (Nasdaq: ICCM) (“Ic |
|
| October 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal ex |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 (Report No.2) Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address |
|
| September 20, 2023 |
IceCure Medical Receives FDA Response to De Novo Classification Request for Breast Cancer Exhibit 99.1 IceCure Medical Receives FDA Response to De Novo Classification Request for Breast Cancer CAESAREA, Israel, September 20, 2023 - IceCure Medical Ltd. (Nasdaq: ICCM), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that the U.S. Food and Drug Administration (“FD |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal |
|
| September 5, 2023 |
IceCure Medical’s ProSense Cryoablation System Receives Regulatory Approval in Brazil Exhibit 99.1 IceCure Medical’s ProSense Cryoablation System Receives Regulatory Approval in Brazil ● $6.6 million in sales expected in Brazilian market over the next five years per distribution agreement guarantees ● High level of early interest in ProSense in South America’s largest market CAESAREA, Israel, September 5, 2023 - IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or the “Company”), deve |
|
| August 28, 2023 |
Exhibit 99.1 IceCure Medical Takes Next Major Initiative as it Prepares to Accelerate the Commercialization of ProSense in U.S. and Canada: Appoints VP of Sales North America ● Mr. Shad Good brings nearly 20 years of medical device sales and leadership experience, including as U.S. Senior Director of Sales at a global leader in minimally invasive breast diagnostic and therapeutic systems ● Immedia |
|
| August 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 (Report No. 2) Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address o |
|
| August 14, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Cautionary Statement Regarding Forward-Looking Statements Certain information included herein may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Forward-looking statements are often characterized by th |
|
| August 14, 2023 |
Exhibit 99.1 ICECURE MEDICAL LTD. UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEET (U.S. dollars in thousands, except share data and per share data) As of June 30, As of December 31, 2023 2022 ASSETS CURRENT ASSETS Cash and cash equivalents 3,031 23,659 Deposit 13,648 - Restricted deposit 296 296 Trade accounts receivable 118 78 Inventory 2,751 2,857 Prepaid expenses and other receivables 58 |
|
| August 14, 2023 |
Exhibit 99.3 IceCure Medical Reports First Half 2023 Financial & Operational Results: Global Adoption of Cryoablation Technology Gaining Momentum ● Company awaits FDA’s response to its regulatory filing for early-stage low risk breast cancer in patients who are at high risk for surgery ● Renowned physician, Dr. Robert Ward, to participate on the Company’s conference call scheduled for today at 10a |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal exe |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal execu |
|
| July 24, 2023 |
Health Canada Approves IceCure Medical’s Minimally Invasive ProSense Cryoablation System Exhibit 99.1 Health Canada Approves IceCure Medical’s Minimally Invasive ProSense Cryoablation System ● Strong interest in ProSense from healthcare providers in Canada strengthens market potential ● ProSense now approved throughout North America CAESAREA, Israel, July 24, 2023 - IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or the “Company”), developer of the ProSense® System, a minimally-invasiv |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal execu |
|
| May 22, 2023 |
IceCure Medical Reports First Quarter 2023 Financial & Operational Results Exhibit 99.1 IceCure Medical Reports First Quarter 2023 Financial & Operational Results · Physician Interest and Adoption of ProSense in the U.S. Builds Momentum as ProSense is Featured at Medical Conferences and Educational Courses · ProSense was the only Cryoablation System Used in a First-of-its-Kind Cryotherapy Continuing Medical Education (CME) course at the American Society of Breast Surgeon |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal execut |
|
| April 27, 2023 |
Exhibit 99.2 ICECURE MEDICAL LTD. CEASEREA, ISRAEL PROXY STATEMENT ANNUAL AND SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 1, 2023 The enclosed proxy statement is being solicited by the board of directors (the “Board of Directors”) of IceCure Medical Ltd. (the “Company”) for use at the Company’s annual and special general meeting of shareholders (the “Meeting”) to be held at on Thurs |
|
| April 27, 2023 |
Exhibit 99.3 ICECURE MEDICAL LTD. ANNUAL AND SPECIAL GENERAL MEETING OF SHAREHOLDERS Date of Meeting: June 1, 2023 PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE ☒ 1. To re-appoint Brightman Almagor Zohar & Co., a firm in the Deloitte Global Network as the independent auditor until the next annual general meeting of the shar |
|
| April 27, 2023 |
ICECURE MEDICAL Ltd. Notice of Annual and SPECIAL General Meeting of shareholders Exhibit 99.1 Dear IceCure Medical Ltd. Shareholders: We cordially invite you to attend the Annual and Special General Meeting of Shareholders of IceCure Medical Ltd. (the “Meeting”), to be held on Thursday, June 1, 2023 at 4:00 p.m. Israel time, by means of remote communication, in a ZOOM conference, in the following link: https://us02web.zoom.us/j/85716046527?pwd=Y1U4QXFhSng5Ni92L3lURG50K08wdz09 |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2023 (Report No. 4) Commission file number: 001-40753 ICECURE MEDICAL Ltd. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| April 20, 2023 |
Exhibit 99.1 IceCure’s ProSense System Used in Endometriosis Cryoablation Study That Demonstrated Efficacy Rate of 92.8% to Avoid Secondary Surgery ● ProSense System among the two types of systems used in the study ● Pain-free survival rates of 93.75% at 6 months and 82.72% at 36 months post-procedure ● 190 million women globally live with endometriosis, for which there is no cure; current treatme |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 (Report No. 3) Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| April 19, 2023 |
Exhibit 99.1 IceCure Medical Ordinary Shares to Trade Exclusively on Nasdaq: Company to Voluntarily Delist Shares from Trading on the Tel Aviv Stock Exchange CAESAREA, Israel, April 19, 2023 – IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternativ |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 (Report No. 2) Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal exec |
